Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma

被引：1
|
作者：
Wheless, Margaret C. [1 ]
Comer, Margaret [2 ]
Gibson, Michael K. [1 ,3 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Sch, Nashville, TN USA
[3] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, 2220 Pierce Ave,777 Preston Res Bldg, Nashville, TN 37232 USA
来源：
CURRENT ONCOLOGY REPORTS | 2024年 / 26卷 / 11期
关键词：
Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Claudin18.2; FGFR; HER-2; PD-L1; Therapy; ADVANCED GASTRIC-CANCER; PEMBROLIZUMAB PLUS CHEMOTHERAPY; SQUAMOUS-CELL CARCINOMA; RANDOMIZED PHASE-III; TRASTUZUMAB EMTANSINE; OPEN-LABEL; PRELIMINARY EFFICACY; SOLID TUMORS; DOUBLE-BLIND; CISPLATIN;
D O I：
10.1007/s11912-024-01607-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose of ReviewThis review highlights advances and recent changes in the treatment paradigm for advanced esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (GEJAC).Recent FindingsChemotherapy remains the backbone of treatment for advanced EAC/GEJAC. New targets/agents include immunotherapy, HER-2, claudin18.2, and FGFR2b, with various mechanisms (CAR-T, bispecific mAB, ADCs) altering the treatment landscape against these targets.SummaryThe approaches to these targets may act together, in sequence, and even synergistically to improve outcomes. Herein, we review the state of the field, including highlighting ongoing clinical trials and additional emerging agents and approaches.
引用
收藏
页码：1469 / 1488
页数：20
相关论文
共 50 条
  • [41] Concurrent versus Sequential Neoadjuvant Chemoradiation Therapy for Esophageal and Gastroesophageal Junction Adenocarcinoma
    Ho, F.
    Torphy, R. J.
    Friedman, C.
    Leong, S.
    Wani, S.
    Scott, C. D.
    Mitchell, J. D.
    Weyant, M. J.
    Meguid, R. A.
    Gleisner, A.
    Goodman, K.
    McCarter, M. D.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S59 - S60
  • [42] Population Based Time Trends in the Epidemiology and Mortality of Gastroesophageal Junction and Esophageal Adenocarcinoma
    Agarwal, Siddharth
    Bell, Matthew G.
    Dhaliwal, Lovekirat
    Codipilly, D. Chamil
    Dierkhising, Ross A.
    Lansing, Ramona
    Gibbons, Erin E.
    Leggett, Cadman L.
    Kisiel, John B.
    Iyer, Prasad G.
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (01) : 246 - 253
  • [43] Adenocarcinoma of the gastroesophageal junction - Preface
    Karpeh, Martin S., Jr.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2006, 15 (04) : XIII - XV
  • [44] Clinicopathologic characteristics and survival outcomes of patients with advanced esophageal, gastroesophageal junction, and gastric adenocarcinoma: a single-institution experience
    Dechaphunkul, A.
    Mulder, K.
    El-Gehani, F.
    Ghosh, S.
    Deschenes, I.
    Spratlin, I.
    CURRENT ONCOLOGY, 2012, 19 (06) : 302 - 307
  • [45] Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
    Pasini, Felice
    Fraccon, Anna Paola
    Modena, Yasmina
    Bencivenga, Maria
    Giacopuzzi, Simone
    La Russa, Francesca
    Gusella, Milena
    de Manzoni, Giovanni
    GASTRIC CANCER, 2017, 20 (01) : 31 - 42
  • [46] Comprehensive Molecular Characterization of Adenocarcinoma of the Gastroesophageal Junction Between Esophageal and Gastric Adenocarcinomas
    Suh, Yun-Suhk
    Na, Deukchae
    Lee, Ju-Seog
    Chae, Jeesoo
    Kim, EuiHyun
    Jang, Giyong
    Lee, Jieun
    Min, Jimin
    Ock, Chan-Young
    Kong, Seong-Ho
    George, Joshy
    Zhang, Chengsheng
    Lee, Hyuk-Joon
    Kim, Jong-Il
    Kim, Seong-Jin
    Kim, Woo Ho
    Lee, Charles
    Yang, Han-Kwang
    ANNALS OF SURGERY, 2022, 275 (04) : 706 - 717
  • [47] Population Based Time Trends in the Epidemiology and Mortality of Gastroesophageal Junction and Esophageal Adenocarcinoma
    Siddharth Agarwal
    Matthew G. Bell
    Lovekirat Dhaliwal
    D. Chamil Codipilly
    Ross A. Dierkhising
    Ramona Lansing
    Erin E. Gibbons
    Cadman L. Leggett
    John B. Kisiel
    Prasad G. Iyer
    Digestive Diseases and Sciences, 2024, 69 : 246 - 253
  • [48] Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus
    Kleinberg, Lawrence
    Brock, Malcolm
    Gibson, Michael
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2015, 16 (07)
  • [49] Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
    Felice Pasini
    Anna Paola Fraccon
    Yasmina Modena
    Maria Bencivenga
    Simone Giacopuzzi
    Francesca La Russa
    Milena Gusella
    Giovanni de Manzoni
    Gastric Cancer, 2017, 20 : 31 - 42
  • [50] Adenocarcinoma of the gastroesophageal junction - Influence of esophageal resection margin and operative approach on outcome
    Barbour, Andrew P.
    Rizk, Nabil P.
    Gonen, Mithat
    Tang, Laura
    Bains, Manjit S.
    Rusch, Valerie W.
    Coit, Daniel G.
    Brennan, Murray F.
    ANNALS OF SURGERY, 2007, 246 (01) : 1 - 8
12345